| Identification | Back Directory | [Name]
CCI 007) | [CAS]
939228-52-1 | [Synonyms]
CCI 007)
CCI-007
(CCI00
Ethyl 2-(4-((2-amino-4-oxothiazol-5(4H)-ylidene)methyl)-2-methoxyphenoxy)acetate | [Molecular Formula]
C15H16N2O5S | [MDL Number]
MFCD34167454 | [MOL File]
939228-52-1.mol | [Molecular Weight]
336.36 |
| Chemical Properties | Back Directory | [Boiling point ]
515.2±60.0 °C(Predicted) | [density ]
1.37±0.1 g/cm3(Predicted) | [storage temp. ]
4°C, protect from light | [solubility ]
DMSO: 25 mg/mL (74.33 mM; ultrasonic and warming and heat to 80°C) | [form ]
Solid | [pka]
-2.32±0.20(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Biological Activity]
CCI-007 is a small molecule with cytotoxic activity against infant leukemia with MLL rearrangements, with IC50 values of 2.5-6.2 μM in sensitive cells[1].
CCI-007 is a selective inhibitor of MLL-r, CALM-AF10 and SET-NUP214 leukemia[1].Following CCI-007 treatment for 24h, significant mitochondrial depolarization was observed in PER-485 cells as evidenced by a shift in JC-1 signal[1].Resistance to CCI-007 can occur by upregulation of MLL target gene expression[1].CCI-007 reverts the aberrant elevated transcription of disease-driving factors HOXA9, MEIS1, and CMYC downstream of the pathogenic MLL fusion protein, thereby inducing MLL-r leukemia cell death[2]. Cell Viability Assay[1] Cell Line: PER-485, MOLM-13, MV4;11 cells. | [References]
[1]. Klaartje Somers, et al. CCI-007, a novel small molecule with cytotoxic activity against infant leukemia with MLL rearrangements. Oncotarget. 2016 Jul 19;7(29):46067-46087.
[2]. Klaartje Somers, et al. A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction. Oncogene. 2019 May;38(20):3824-3842. |
|
| Company Name: |
InvivoChem
|
| Tel: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
| Company Name: |
nanjing
|
| Tel: |
13376082704 13376082704 |
| Website: |
www.linye-e.com/ |
|